A detailed history of Nikko Asset Management Americas, Inc. transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Nikko Asset Management Americas, Inc. holds 2,592,198 shares of VERV stock, worth $13.5 Million. This represents 0.34% of its overall portfolio holdings.

Number of Shares
2,592,198
Previous 2,397,604 8.12%
Holding current value
$13.5 Million
Previous $33.4 Million 3.0%
% of portfolio
0.34%
Previous 0.32%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 02, 2024

BUY
$10.81 - $17.96 $2.1 Million - $3.49 Million
194,594 Added 8.12%
2,592,198 $34.4 Million
Q4 2023

Feb 08, 2024

BUY
$8.84 - $18.7 $2.21 Million - $4.68 Million
250,361 Added 11.66%
2,397,604 $33.4 Million
Q3 2023

Nov 09, 2023

SELL
$11.42 - $20.82 $440,971 - $803,943
-38,614 Reduced 1.77%
2,147,243 $28.5 Million
Q2 2023

Aug 14, 2023

BUY
$13.34 - $19.9 $7.84 Million - $11.7 Million
587,863 Added 36.79%
2,185,857 $41 Million
Q1 2023

May 03, 2023

BUY
$14.3 - $24.01 $5.28 Million - $8.87 Million
369,547 Added 30.08%
1,597,994 $23 Million
Q4 2022

Feb 13, 2023

BUY
$17.85 - $40.7 $8.08 Million - $18.4 Million
452,750 Added 58.37%
1,228,447 $23.8 Million
Q3 2022

Nov 14, 2022

BUY
$15.63 - $41.49 $10.3 Million - $27.4 Million
660,465 Added 573.16%
775,697 $24.4 Million
Q2 2022

Aug 04, 2022

BUY
$11.14 - $23.17 $547,230 - $1.14 Million
49,123 Added 74.31%
115,232 $1.49 Million
Q1 2022

May 06, 2022

SELL
$20.92 - $39.36 $101,273 - $190,541
-4,841 Reduced 6.82%
66,109 $1.32 Million
Q4 2021

Feb 08, 2022

SELL
$31.94 - $54.82 $238,623 - $409,560
-7,471 Reduced 9.53%
70,950 $2.27 Million
Q3 2021

Nov 09, 2021

BUY
$46.0 - $73.99 $3.61 Million - $5.8 Million
78,421 New
78,421 $3.61 Million

Others Institutions Holding VERV

About Verve Therapeutics, Inc.


  • Ticker VERV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,942,300
  • Market Cap $311M
  • Description
  • Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...
More about VERV
Track This Portfolio

Track Nikko Asset Management Americas, Inc. Portfolio

Follow Nikko Asset Management Americas, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nikko Asset Management Americas, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Nikko Asset Management Americas, Inc. with notifications on news.